CurrentBlue Cross Blue Shield - IowaPolicy 05.02.36

Immediate-release opioid combination products (acetaminophen/aspirin/ibuprofen-containing)

Defines coverage, quantity limits, and accumulation rules for immediate-release opioid combination products (brand and generic) including specific drug/strength monthly and 3-month limits tied to FDA-labeled daily dosing, 90 MME/day ceiling (unless FDA-labeled max exceeds 90 MME/day), and maximum non-opioid component daily limits (4 g APAP/ASA, 3200 mg ibuprofen).

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyImmediate-release opioid combination products (acetaminophen/aspirin/ibuprofen-containing)

Policy CodePolicy 05.02.36

Change TypeReviewed Apr 2024revised Apr 2023 (no material clinical changes)

Effective DateJul 1, 2023

Next Review Date

Key ActionClaims will reject with a message indicating quantity limits are exceeded if a patient requests more than the initial monthly or 3-month quantity limit or if accumulation would exceed APAP/ASA/ibuprofen or MME thresholds.

SourceLink

POLICY UPDATE CHANGES

Current effective date July 1, 2023; policy reviewed April 2024, revised April 2023.

ManyCovered drug/strength entries

90MME ceiling for initial limits

4Acetaminophen/aspirin max (g/day)

3200

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary & Conditions

Coverage stance: covered_with_criteria.

This policy defines coverage, quantity limits, and accumulation rules for immediate-release opioid combination products (brand and generic) that contain non-opioid components such as acetaminophen, aspirin, or ibuprofen.

Coverage is provided without prior authorization for a 30-day or 90-day supply when the monthly quantity does not exceed the product's FDA-labeled maximum daily dosing, and when monthly quantities correspond to < 90 MME/day unless the product's FDA-labeled maximum strength/dosage frequency exceeds 90 MME/day.

All covered products must also stay within the maximum daily limits for non-opioid components: 4 g/day (4000 mg/day) acetaminophen or aspirin and 3200 mg/day ibuprofen.

Coverage Conditions

Coverage is provided without prior authorization when ALL of the following are met:

ALL of the following

Immediate-release combination product: Prescription is for an immediate-release combination product opioid (includes non-opioid components acetaminophen, aspirin, or ibuprofen).
Supply requested is a 30-day or 90-day supply with monthly quantity not exceeding the maximum daily dose listed in product labeling.
Uses 25 days for 30-day fill and 75 days for 90-day fill to allow processing.
Monthly quantity limits: Monthly quantities correspond to < 90 MME/day and contain < 4 g/day acetaminophen or aspirin and < 3200 mg/day ibuprofen, unless the FDA-labeled maximum strength/dosage frequency exceeds 90 MME/day.MME < 90/day; APAP/ASA < 4 g/day; IBU < 3200 mg/day
Unless maximum FDA-labeled strength/dosage frequency exceeds 90 MME/day.
Member eligibility: Member has no exclusions to the prescribed therapy and applicable contract benefits allow coverage.
Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply.

Quantity Limit Rejection

Claims will reject when ANY of the following are true:

ANY of the following

Exceeds initial quantity: Patient is requesting more than the initial quantity limit (monthly or 3-month) specified for the drug/strength.
Claims will reject with a message indicating quantity limits are exceeded.
Exceeds cumulative limits: Requested quantity would exceed cumulative limits for the accumulation group (see accumulation rules) resulting in > 4 g/day APAP or ASA or > 3200 mg/day ibuprofen or > 90 MME/day (unless FDA-labeled max exceeds 90 MME/day).APAP/ASA > 4 g/day; IBU > 3200 mg/day; MME > 90/day
Accumulation groups apply across listed product groups and limits use processing windows (25 days for 30-day, 75 days for 90-day).

Thresholds

Maximum acetaminophen or aspirin per day4 g/day (4000 mg/day)

Maximum ibuprofen per day3200 mg/day

MME ceiling for quantity limits< 90 MME/day unless FDA‑labeled max strength/dosage frequency exceeds 90 MME/day

Policy Identifier & Codes

Policy Identifiermixed

05.02.36

Policy number (Policy #: 05.02.36)

Provider Actions & Billing Rules

Billing Rule

Quantity limit enforcement and claim rejection

Claims will reject with a message indicating quantity limits are exceeded if a patient requests more than the initial monthly or 3-month quantity limit for the drug/strength or if accumulation would exceed APAP/ASA/ibuprofen or MME thresholds.

Documentation Required

Benefit verification and medical necessity

Verify individual member benefits and contract language; Wellmark determines medical necessity only if the benefit exists and no contract exclusions apply.

Background & Definitions

This policy aligns quantity limits for immediate-release opioid combination products with FDA-labeled daily dosing and the CDC Clinical Practice Guideline for Prescribing Opioids for Pain.

Quantity limits are set so monthly supplies do not exceed the product labeling daily maximums and generally correspond to < 90 MME/day, with an exception when the FDA-labeled maximum strength/dosage frequency exceeds 90 MME/day.

Because immediate-release opioid combination products include non-opioid components that have their own FDA-labeled daily maximums, the policy enforces additional safety limits of 4 g/day acetaminophen or aspirin and 3200 mg/day ibuprofen. These non-opioid component limits apply to all patients regardless of concomitant conditions (for example, cancer, sickle cell disease, palliative or end-of-life care).

Claims will reject if a patient requests more than the initial monthly or 3-month quantity limit or if accumulation across grouped products would exceed the APAP/ASA/ibuprofen or MME thresholds.

Initial Month Limit: Quantity allowed for a 30-day fill period (uses a 25-day duration for processing) aligned to daily dosing and MME/APAP/ASA/IBU limits.

Initial 3 Month Limit: Quantity allowed for a 90-day fill period (uses a 75-day duration for processing) aligned to daily dosing and MME/APAP/ASA/IBU limits; may be 'Does Not Apply' for drugs indicated only for short-term use.

Accumulation groups: Drugs accumulate into five groups for quantity limits: 1) APAP-containing solutions/suspensions/elixirs; 2) APAP-containing tablets/capsules; 3) Aspirin-containing tablets/capsules; 4) Ibuprofen-containing tablets; 5) Celecoxib-containing tablets.

Clinical Evidence & Guidelines

Evidence: The policy references the Centers for Disease Control and Prevention Clinical Practice Guideline for Prescribing Opioids for Pain (2016) and the 2022 update, which inform cautious prescribing, recommend lowest effective dosages, and note risks increase with higher MME levels.

The guideline supports setting quantity limits aligned with limiting opioid dosages (noting limited benefit and increased risk above certain MME thresholds) and informs the policy's < 90 MME/day ceiling for initial quantity limits.

Revision History

2023-07-01effective_date

Current effective date set to July 1, 2023; revision history indicates no material clinical policy statement changes since last review.

2024-04-01policy_reviewedLatest

Policy reviewed April 2024; revision history present but document indicates no clinical policy statement changes since last review (is_material: false).

2023-04-01policy_revised